Factors For Recurrence In Acute Central Serous Chorioretinopathy Patients Underwent One-Third Dose Verteporffn Photodynamic Therapy

To investigate the factors for recurrence in acute central serous chorioretinopathy (aCSC) for patients who underwent one-third dose verteporffn photodynamic therapy (PDT). 

In patients with aCSC, PDT can provide faster subretinal fluid resolution, more rapid recovery of visual impairment. Furthermore, reduced-intensity PDT, such as half-inffuence, half-dose, and half-time PDT were also developed given the severe complication-profound angiographic closure caused by full-dose PDT. Recently, one-third dose PDT has been testiffed as a safe and reliable treatment option for CSC, while recurrence of CSC developed in some cases.

A retrospective study was performed in aCSC patients treated with one-third dose PDT and followed up for 36 months. Demographic information and clinical features were compared. A logistic regression model was used to evaluate the associated factor of aCSC recurrence. 

There were 162 patients with aCSC included in current study.36-month after one-third dose PDT, good recovery was identiffed in 131 patients,whereas 31 cases developed recurrence. Signiffcant between-group differences were observed in baseline age,the right,left and both eyes,best-corrected visual acuity,presenting with pigment epithelium detachment,retinal pigment epithelium damage and subfoveal choroidal thickness level (P=0.005,P<0.001,P<0.001,P<0.001,P=0.006,and P<0.001,respectively).The recurrence of aCSC was associated with presenting with PED(odds ratio=1.78;95% CI,1.45–1.98;P<0.001),RPE damage(OR=1.13;95%CI:1.08–1.23;P<0.001),baseline BCVA (OR= 0.96;95%CI:0.95-0.99;P=0.001),and SCT level (OR=1.18; 95%CI:1.02–1.20;P<0.001). 

In acute CSC after treatment of one-third dose PDT, recurrence is associated with RPE damage, baseline BCVA and SCT level. Our ffndings will assist clinicians to evaluate aCSC in clinical practice and provide insights into the prevention of recurrence.